


ITM Symposium at the DGN 2022

On behalf of ITM I would like to invite you to our DGN Symposium “Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective” on Thursday, 28. April 2022, 12:30 - 13:30 pm, room 2 at the Leipzig Congress Centre.

Our symposium will be chaired by Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, and the faculty will consist of Prof. Dr. *Wolfgang Wadsak*, Head of Medicinal Radiochemistry and Biomarker Development, Medical University of Vienna, and Neil Quigley, Global Product Manager, ITM.

The in-house preparation of radiopharmaceuticals has resulted in major developments in the field of nuclear medicine and precision oncology, including the development of prostate cancer and neuroendocrine tumor treatment. The symposium will provide an introduction and overview of the current status of in-house preparation with some recent developments that can be attributed to it.

I look forward to you joining us in what promises to be an exciting overview of recent developments and radiopharmacy perspective with critical analysis of the latest science and clinical practice that is driving the Targeted Radionuclide Therapy paradigm into the forefront of patient management.



Steffen Schuster, CEO ITM

Program

Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective

Chair: Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, Munich

- **Recent Developments: New Targets and Emerging ^{225}Ac -Therapies**
Neil Quigley, Global Product Manager, ITM, Munich
- **Die Herstellung von Radiopharmaka zur unmittelbaren Anwendung – essentieller Baustein und Innovationstreiber in der Nuklearmedizin**
Prof. Wolfgang Wadsak, Leiter der Medizinischen Radiochemie und Biomarkerentwicklung der klinischen Abteilung für Nuklearmedizin, Universitätsklinikum AKH Wien
- **Serving Future Global Demand of n.c.a. ^{177}Lu and Development of ^{225}Ac**
Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, Munich
- **Q&A Session**